Boston, MANCT06639464Now EnrollingIRB Ready

Opioid Use Disorder Clinical Trial in Boston, MA

Access cutting-edge opioid use disorder treatment through this phase 2 clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Brigham and Women's Hospital

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access opioid use disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related opioid use disorder treatment provided free

Apply for This Boston Location

Check if you qualify for this opioid use disorder clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Opioid Use Disorder Study in Boston

The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching placebo (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD. The secondary aim is to assess the preliminary efficacy, safety, and tolerability of semaglutide for OUD.

Sponsor: Brigham and Women's Hospital

Who Can Participate

Inclusion Criteria

English speaking adults aged 18 and above
DSM-5 diagnosis of opioid use disorder, severe
Initiated sublingual buprenorphine (SL-BUP) treatment within 60 days of enrollment
Attained stable dosing of SL-BUP of 16mg or greater for 30 days prior to enrollment
Anticipating continuation of SL-BUP for the duration of the trial
Agreeable with bringing SL-BUP prescription to visits to allow study team to conduct a dose count
Willing to grant study team permission to communicate about SL-BUP treatment with community prescriber via completion of 42 CFR release Individuals with any of the following will be excluded:
DSM-5 diagnosis of any current substance use disorder excluding opioid, cannabis or tobacco
Active psychosis, active suicidality or homicidality or any psychiatric condition that impair ability to provide informed consent
Any current or lifetime diagnosis of eating disorders
BMI\<25mg/kg2
Current or lifetime diagnosis of Type 1 or Type 2 diabetes
Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Use of any GLP-1 agonist medications in the prior 3 months
Anticipating receipt of any GLP-1 agonist medications during the trial
History of angina pectoris, coronary heart disease, congestive heart failure, inflammatory bowel disease, chronic obstructive pulmonary disease, bariatric surgery, idiopathic pancreatitis, diabetic gastroparesis
Liver function test greater than 3 times upper normal limit
Renal impairment as indicated by eGFR of \<60
History of hypersensitivity or allergy to semaglutide
Pregnant or breastfeeding
Anticipated to participate in a concurrent drug trial
Any other reason or clinical condition that the investigators judge may interfere with study participation and/or be unsafe for a participant

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06639464) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Opioid Use Disorder Treatment Options in Boston, MA

If you're searching for opioid use disorder treatment options in Boston, MA, this clinical trial (NCT06639464) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced opioid use disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all opioid use disorder clinical trials near you to find additional studies recruiting in your area.

More Substance Use Disorder Trials in Boston, MA

See all substance use disorder clinical trials recruiting in Boston — not just this study.

Browse Substance Use Disorder Trials in Boston →

Browse More Trials by Condition

Substance Use Disorder TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA